Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

文献中の引用(63)

カスタマーフィードバック(12)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M1z3OmN6fG:2b4jpZ{BCe3OjeR?= NX23NZZtOTBibl2= NWHKNXZpPzJiaB?= NFHwSYhFVVOR MmHyVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 MYqyOFkxODh5Mx?=
HT-29 NVTnPINXS3m2b4TvfIlkKEG|c3H5 MoTFNVAhdk1? MlXqO|IhcA>? NIjSZ4FFVVOR NHGyXYVRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= NFn1[oQzPDlyMEi3Ny=>
HT-29 MYLDfZRwfG:6aXOgRZN{[Xl? NEnMdnYyOCCwTR?= MWm3NkBp MlzDSG1UVw>? M4rINHBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NXH3[5I3OjR7MEC4O|M>
PC3 NWexe2NbU2mwYYPlJGF{e2G7 NYrkcIhkOTByIH7N NGXZS4oyKGh? NV\qd5FqTE2VTx?= NEXqWmJRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=> MVSyNVk4QDZ6Mx?=
PC3 NU\WOo9nU2mwYYPlJGF{e2G7 MV[xNFAhdk1? MYGxJIg> M{j6e2ROW09? MYPEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MkTXNlE6Pzh4OEO=
PC3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mke2NU42KM7:TR?= NXfQco97OSCq Mmj4SG1UVw>? MnraTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P M4\peVIyQTd6Nkiz
HEK293 Mn6ySpVv[3Srb36gRZN{[Xl? NIPpPGQyODBibl2= MUO4JIg> NXTMfHk3TE2VTx?= NInYUnVKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= Mn7hNlE2Ozl|MEG=
BT-20 MWrLbY5ie2ViQYPzZZk> MX2yNEDPxE1? NIO3T5NFVVOR MWrEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? MVOyNVM2OzV3MR?=
U937 NEnLeI5CdnSrYnHjeIVzcWGuIFHzd4F6 MoC5OVAh|ryP M1eyWFQ5KGh? Mm\hSG1UVw>? NILDXo1KdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= MYqyNVE1OjFyNh?=
U937 M1HCUWFvfGmkYXP0[ZJq[WxiQYPzZZk> NU[zbIRoPTBizszN NVjRVo94PDhiaB?= MVzEUXNQ NVqxbGRGTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= NYHvbZZnOjFzNEKxNFY>
U937 NVvHVJVvSW62aXLhZ5RmemmjbDDBd5NigQ>? MWC1NEDPxE1? MX[0PEBp MmjxSG1UVw>? Mn\uSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> NEP2XHkzOTF2MkGwOi=>
MCF-7 MnXnRZV1d3CqYXf5JGF{e2G7 M4jFXVMxKG6P Mn3kOEBp M1TPNWROW09? M4TDU2lv\HWlZYOgZZV1d3CqYXf5 NFPrVVczODB{OEGzOC=>
U87MG NFz5eYtMcW6jc3WgRZN{[Xl? NEPRTIIyKM7:TR?= M3PTSlYhcA>? NXfQT4c3TE2VTx?= MoTDVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? NFe2eHcyQTh2OESwOC=>
U87MG NYj2N2loU2mwYYPlJGF{e2G7 MknPNUDPxE1? MU[2JIg> MVXEUXNQ NV;TS|hMWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> MXmxPVg1QDRyNB?=
U87MG M2HBNWtqdmG|ZTDBd5NigQ>? MUGxJO69VQ>? MYW2JIg> M4XWcWROW09? NFj4eolFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= MonyNVk5PDh2MES=
U87MG MmTDT4lv[XOnIFHzd4F6 MnvDNUDPxE1? M4[ycVYhcA>? NYfMRZdKTE2VTx?= Mn\WSI9meyCwb4SgbY5pcWKrdDDQMVRGSlBzKGSzO{81PilicHjvd5Bpd3K7bHH0bY9v NUO2fmh1OTl6NEi0NFQ>
COS7 cells expressing EGFP-HDQ74/rheb NHq1V21CfXSxcHjh[5khSXO|YYm= M4DEZlAvOiEQvF2= NYfsS3dJOjRiaB?= MlHRSG1UVw>? MYfJcoR2[2W|IHH1eI9xcGGpeR?= NWLmNpJYOTh|OUG5OFk>
COS7 cells expressing EGFP-LC3 NFj1VY9CfXSxcHjh[5khSXO|YYm= M3W0[FAvOiEQvF2= Mli3NlQhcA>? MYTEUXNQ NEfSVohKdmS3Y3XzJIF2fG:yaHHnfS=> M4HHWFE5OzlzOUS5
H4 M17FTmZ2dmO2aX;uJGF{e2G7 MkfJNE4zKM7:TR?= NXzpelJ5OjRiaB?= NXnHZWlYTE2VTx?= MYjJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz MXqxPFAzPDV6NB?=
HeLa NEDIRm9HfW6ldHnvckBCe3OjeR?= MnfGNVAxKG6P NFvaUI4{PiCq MYfEUXNQ MYLJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u M{\pU|E4PTZ|M{i1
HeLa NILMN2RHfW6ldHnvckBCe3OjeR?= MXixNFAhdk1? NIrBR3c{PiCq NUL0b5QxTE2VTx?= NYXhZnhnUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w NFfhU|MyPzV4M{O4OS=>
HeLa NFriU2VHfW6ldHnvckBCe3OjeR?= M{j3fVExOCCwTR?= NFjqNHY{PiCq M125NmROW09? MonUTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MmLlNVc2PjN|OEW=
SYF NIPpXpRHfW6ldHnvckBCe3OjeR?= MV:xNFAhdk1? NXXWV3hKOjRiaB?= NWLRS4ZbTE2VTx?= M1S2Wmlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> Mk\mNVc2PjN|OEW=
SYF NY\5eZBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWzSHEyODBibl2= MYmyOEBp NILGXHJFVVOR NHXVbm9KdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz NF7tfJcyPzV4M{O4OS=>
HEK293T M1;6S2FvfGm4aYLhcEBCe3OjeR?= MlK0NUBvVQ>? M3PnXVQh\A>? M1jBTGROW09? NGrscVJKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> NVvLbIxtOTd2OEW1NFE>
HEK293T M2rZXmFvfGm4aYLhcEBCe3OjeR?= NVLXfJlDOSCwTR?= NWG3eY5NPCCm Ml7SSG1UVw>? MXrJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NVHVU5VkOTd2OEW1NFE>
PBMC MWHGeY5kfGmxbjDBd5NigQ>? MV:xJI5O MlH0NVQh\A>? MWjEUXNQ M4HIZnJm\HWlZYOgR2NTPSCmZX7zbZR6 MVKxO|Q5PTVyMR?=
PBMC NY[zW2p3TnWwY4Tpc44hSXO|YYm= MWOxJI5O MlfMNVQh\A>? Ml[1SG1UVw>? NFPDPHVFd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? NFP6SJgyPzR6NUWwNS=>
HEK293 cells NUDOOWFXU2mwYYPlJGF{e2G7 MVi1NEBvVQ>? NXXXWmwyPDVibXnu MnzQSG1UVw>? M2r6R2lvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? NWfVV41[OTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MoewSpVv[3Srb36gRZN{[Xl? M1nhTVExOCCwTR?= NWDx[VFuPCCq NICxeXVFVVOR M{O1O2lv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk NHfDe5MyPzF{OEK2Ni=>
Human mixed lymphocyte M4fwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC5OUBvVQ>? MWjEUXNQ MmPWTWM2OD1zLk[gcm0v NXmybYpPOTZzOEW4OlU>
Lewis rat lymph node cells NVfRVmhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LGWlUh|ryP M2XlWGROW09? NIKyZXNKSzVyPUKuOkDPxE1? M1fF[lE3OTh3OE[1
cells from the thymus of normal BALB/c mice NXTYVoN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7YbFIyOCCwTR?= MYi3NkBp NFXaT3pFVVOR NWGyUnE5UW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> M3PGUFExODJzOUS4
MRK-nu-1 NGW5R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m5RmlEPTB;MD64OFUheE1? MYDTRW5ITVJ?
OCUB-M NXPZ[4p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDrTWM2OD13LkK0JJBO NUjlSotSW0GQR1XS
SF539 NW\lfoFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHjXo5KSzVyPUGxMlYheE1? Ml3SV2FPT0WU
ES4 NULzVHYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTSTWM2OD1{MT61JJBO NX3tNXJkW0GQR1XS
RL95-2 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\0dXN6UUN3ME2xNFcheE1? M3nKNXNCVkeHUh?=
LC-2-ad MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzzTWM2OD12MkOgdG0> NUC2WHFNW0GQR1XS
Daudi MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTx[XhKSzVyPUSzOEBxVQ>? MmXBV2FPT0WU
NTERA-S-cl-D1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLnTWM2OD12NEOgdG0> MoHYV2FPT0WU
OS-RC-2 NVnGOHVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjETWM2OD14NUKgdG0> Mo\KV2FPT0WU
VA-ES-BJ M1jpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHkTWM2OD15MkOgdG0> NFLmNYpUSU6JRWK=
GR-ST MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETBeJhKSzVyPUi0OkBxVQ>? NFHiTW1USU6JRWK=
SW872 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLDbHNnUUN3ME24OFYheE1? NGHN[mxUSU6JRWK=
NOS-1 MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rC[mlEPTB;OEexJJBO NHrsc45USU6JRWK=
MC116 M{Xwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PZR2lEPTB;OUi1JJBO Mnj5V2FPT0WU
NCI-H1355 Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwMEGgcm0> NVX0Wo14W0GQR1XS
RPMI-8226 NF63PYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fSeWlEPTB;MT6xPUBvVQ>? NEDmUYdUSU6JRWK=
TE-15 NUT1cXJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwM{[gcm0> NIjJZZVUSU6JRWK=
Ramos-2G6-4C10 NH3PdVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX75fYRmUUN3ME2xMlQ3KG6P MoH2V2FPT0WU
KU812 NHrCTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PHN2lEPTB;Mj6wNUBvVQ>? MW\TRW5ITVJ?
EW-1 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwMUegcm0> M17lWHNCVkeHUh?=
KS-1 Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXGTWM2OD1{LkS1JI5O NH7yPJVUSU6JRWK=
SK-LMS-1 MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwNEmgcm0> NIfRdGFUSU6JRWK=
TGBC1TKB NFHieoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTXTWM2OD1{Lk[5JI5O NHuzbppUSU6JRWK=
TE-6 M4jrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i2d2lEPTB;Mj63O{BvVQ>? NF\6bY5USU6JRWK=
ETK-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mly2TWM2OD1{LkiyJI5O MVXTRW5ITVJ?
BE-13 NHXkUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJwOUmgcm0> MXfTRW5ITVJ?
A3-KAW NFyzcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzFTWM2OD1{Lkm5JI5O MXzTRW5ITVJ?
TE-10 MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rwcWlEPTB;Mz6zJI5O MVvTRW5ITVJ?
DOHH-2 NXvzOo9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S1PGlEPTB;Mz6zOUBvVQ>? Mlr4V2FPT0WU
ES6 NYjUTY1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrocIlFUUN3ME2zMlQ{KG6P M{LWR3NCVkeHUh?=
OPM-2 M1rIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTRwMUWgcm0> M1jCUnNCVkeHUh?=
SH-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G3fWlEPTB;ND6zOEBvVQ>? NF;KboVUSU6JRWK=
NB13 M1y5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXldJNKSzVyPUSuN|Yhdk1? NHPLWVdUSU6JRWK=
HUTU-80 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRwNEKgcm0> NUi0[lhxW0GQR1XS
CCRF-CEM NUHIZ5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjXU4hKSzVyPUSuPVQhdk1? MYjTRW5ITVJ?
TGBC24TKB MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTVwNUGgcm0> M3LIOnNCVkeHUh?=
697 M1mxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nVV2lEPTB;Nj6yPEBvVQ>? NG\jR5FUSU6JRWK=
J-RT3-T3-5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTZwNE[gcm0> MkPxV2FPT0WU
KALS-1 NIXEdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF20UGVKSzVyPU[uOVYhdk1? NHLB[IxUSU6JRWK=
no-10 M{nMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnQO2dqUUN3ME23MlI6KG6P MX7TRW5ITVJ?
SK-NEP-1 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm1UW1OUUN3ME24Mlc6KG6P NVnhOmJlW0GQR1XS
L-540 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrmTVVFUUN3ME2xNE41OiCwTR?= NULEVng4W0GQR1XS
JiyoyeP-2003 NEfGcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDsemFKSzVyPUGwMlk1KG6P NXrnfJJTW0GQR1XS
HH MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrTUGJlUUN3ME2xNU4{QSCwTR?= NWSzPJI2W0GQR1XS
SR MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTse3RVUUN3ME2xNU41PSCwTR?= NUDu[XZJW0GQR1XS
QIMR-WIL NVnLSFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrESYNlUUN3ME2xNU45PSCwTR?= NH3MTZZUSU6JRWK=
A4-Fuk M37wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOTWRKSzVyPUGzMlEzKG6P MXTTRW5ITVJ?
CESS MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPXTWM2OD1zMz6xN{BvVQ>? MnLuV2FPT0WU
KE-37 M2rGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Pxd2lEPTB;MU[uNFchdk1? MVrTRW5ITVJ?
SK-UT-1 NVHlU5ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jRW2lEPTB;MU[uPFEhdk1? MlnYV2FPT0WU
SIG-M5 NWjQeXhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnOZWxKSzVyPUG3MlI2KG6P M{[zb3NCVkeHUh?=
HT NHLJbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WyPWlEPTB;MUeuOkBvVQ>? Ml\DV2FPT0WU
DEL NHHJ[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXX[ppsUUN3ME2xO{46QSCwTR?= MV7TRW5ITVJ?
SK-PN-DW NVH2T2hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rqcWlEPTB;MkCuNlMhdk1? M{PucHNCVkeHUh?=
RPMI-8402 NX3iWmttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fQcGlEPTB;MkGuO|chdk1? MXPTRW5ITVJ?
RPMI-6666 NFjmU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD1{ND60NkBvVQ>? Mn70V2FPT0WU
NCI-H720 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr6TWM2OD1{NT60NUBvVQ>? Mn\nV2FPT0WU
EW-16 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrHSpdKSzVyPUK2Mlg4KG6P MXHTRW5ITVJ?
BL-70 MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn6R3lKSzVyPUK4MlM5KG6P MV7TRW5ITVJ?
SF126 M3f6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSyTWM2OD1|MD6zPEBvVQ>? NF3wWoFUSU6JRWK=
BC-1 M1jlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTpTWM2OD1|MT6yOkBvVQ>? M3e2eXNCVkeHUh?=
MHH-PREB-1 NYrBUYl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN{LkS0JI5O M3fqO3NCVkeHUh?=
A101D MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTN{Lk[yJI5O NH;TRoFUSU6JRWK=
NMC-G1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWxRWZKSzVyPUOzMlY4KG6P MkLZV2FPT0WU
LB1047-RCC MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN2Lk[5JI5O NEfhSppUSU6JRWK=
EM-2 M{Hob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTN6LkWzJI5O NH3QU|ZUSU6JRWK=
COLO-684 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPR[4VKSzVyPUO5Mlghdk1? MWPTRW5ITVJ?
Becker MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVThZWhTUUN3ME20NU4xPSCwTR?= NFi0XJpUSU6JRWK=
BL-41 MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnBOGRKSzVyPUSzMlY3KG6P NWPNZ4N4W0GQR1XS
MDA-MB-134-VI NFraRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHjNYRwUUN3ME20OE4xOiCwTR?= NHT5dXhUSU6JRWK=
L-363 MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPG[YtKSzVyPUS0Mlc{KG6P MnjuV2FPT0WU
ECC4 NFyzfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoThTWM2OD12ND63PEBvVQ>? MYnTRW5ITVJ?
A388 M1rPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPN[mZKSzVyPUS0MlgzKG6P NV\KbYZRW0GQR1XS
HEL M{nHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTR7Lke5JI5O NWXrVpA{W0GQR1XS
RKO NXnKPZRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17QXGlEPTB;NUCuNlkhdk1? M4f4cnNCVkeHUh?=
KINGS-1 MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTVzLkW1JI5O MXLTRW5ITVJ?
EB-3 MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKyUmFKSzVyPUWyMlY4KG6P MXvTRW5ITVJ?
ARH-77 NIfkZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrre2NjUUN3ME21Nk45KG6P NVXX[GxMW0GQR1XS
GCIY NVXBXVY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\OOmlEPTB;NUOuOFYhdk1? NIS4cWJUSU6JRWK=
NCI-H1304 NFWxd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\5TWM2OD13Nz6yNkBvVQ>? MXnTRW5ITVJ?
KARPAS-299 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37We2lEPTB;NkGuPFIhdk1? M3j6OHNCVkeHUh?=
IA-LM NIjBW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MortTWM2OD14OD6xN{BvVQ>? NYn2XnVrW0GQR1XS
GI-1 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTdyLkO5JI5O NHroR5FUSU6JRWK=
TE-11 NH;jTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXkOIJyUUN3ME23O{4yPyCwTR?= M2DZXnNCVkeHUh?=
LS-411N NFPmTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTd5LkW3JI5O M1m0b3NCVkeHUh?=
no-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LHXmlEPTB;OEOuNlQhdk1? M3PEc3NCVkeHUh?=
MV-4-11 NHvYbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITreFlKSzVyPUizMlc{KG6P NXHMVXVxW0GQR1XS
BV-173 M4H2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HWTWlEPTB;OEOuPVchdk1? MoL0V2FPT0WU
CMK NUDiXII6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfaSWNPUUN3ME24OE4yPiCwTR?= NXvxVpRzW0GQR1XS
LC4-1 NYDwUlg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;BTWM2OD16Nj63NkBvVQ>? MVLTRW5ITVJ?
COR-L279 NH;1WlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK5SoJKSzVyPUi3MlI2KG6P Mki1V2FPT0WU
NCI-H209 NVrXPXQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HLWmlEPTB;OEeuOFEhdk1? MonGV2FPT0WU
Raji M3ruV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL4TWM2OD16OT63NkBvVQ>? MmHZV2FPT0WU
LB996-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;tSnVKSzVyPUmzMlQ{KG6P MkXMV2FPT0WU
NCI-H526 NYTWO3RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLsWGxKSzVyPUmzMlU6KG6P NIroWJhUSU6JRWK=
KGN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jUN2lEPTB;OU[uNlkhdk1? M2DvVnNCVkeHUh?=
MOLT-4 NIXMNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTl4Lke5JI5O MnvrV2FPT0WU
PF-382 M2fQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf4RmlKSzVyPUm2Mlc6KG6P NIHMUFdUSU6JRWK=
BC-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y3XWlEPTB;OUmuNVghdk1? Mn3WV2FPT0WU
KARPAS-422 NHK2XGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFyMj6wPUBvVQ>? NIjUR|RUSU6JRWK=
SBC-1 Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\zSYtKSzVyPUGwO{44PSCwTR?= Mof3V2FPT0WU
LC-1F NVmzbmQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HQ[GlEPTB;MUC4MlA2KG6P MWrTRW5ITVJ?
GB-1 M4\QT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFyOT6wNkBvVQ>? NVu1W5BxW0GQR1XS
SNB75 M3vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS2TWM2OD1zMUmuOlkhdk1? NWPJWY5PW0GQR1XS
BB65-RCC M4XHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO5TWM2OD1zMUmuPVMhdk1? NVnQRmdjW0GQR1XS
NCI-N87 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfkWJhKSzVyPUGyNU46QCCwTR?= M1TuXnNCVkeHUh?=
IST-MEL1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF{Mj6zPEBvVQ>? MVvTRW5ITVJ?
HOP-62 NVn3T3FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DrdWlEPTB;MUK2Mlg6KG6P MY\TRW5ITVJ?
ACN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTMTWM2OD1zNE[uO|Uhdk1? NYXLR2xSW0GQR1XS
DMS-114 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF3MD62O{BvVQ>? M{XsUHNCVkeHUh?=
MLMA NF7iUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr6b4oxUUN3ME2xOVkvQDhibl2= NH72TmpUSU6JRWK=
HT-144 MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:wfFZKSzVyPUG2OU41OyCwTR?= M2X1N3NCVkeHUh?=
C2BBe1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HuNmlEPTB;MU[3Mlc3KG6P Mmr5V2FPT0WU
L-428 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\tTWM2OD1zN{euO{BvVQ>? M1izOHNCVkeHUh?=
DU-4475 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2OzTmlEPTB;MUi3MlY5KG6P MVPTRW5ITVJ?
CP67-MEL MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLt[pBsUUN3ME2xPVkvOzhibl2= M4Cxc3NCVkeHUh?=
MEG-01 NEfGXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TETWlEPTB;MkCxMlk3KG6P MlywV2FPT0WU
IST-SL2 M4jJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7UTWM2OD1{MEiuOlMhdk1? NGflUHVUSU6JRWK=
ES8 M3zKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHtOoZjUUN3ME2yNlUvQTRibl2= M4LEPXNCVkeHUh?=
COLO-800 NU\yT49RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\WT5RYUUN3ME2yN|UvOjhibl2= M4ric3NCVkeHUh?=
MFH-ino NIXl[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\mUJNKSzVyPUKzOU45PCCwTR?= NXjacWxTW0GQR1XS
OVCAR-4 NWDJTVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ|Nz6yOEBvVQ>? M4PvXnNCVkeHUh?=
PSN1 NWPVOYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ2Mj63NUBvVQ>? MV3TRW5ITVJ?
EW-12 NFTDNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorGTWM2OD1{NEOuNUBvVQ>? NGDvTJZUSU6JRWK=
HCC1599 NUTEVXdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzWTWM2OD1{NkGuOFchdk1? NWexXIk4W0GQR1XS
SJSA-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnIfmhKSzVyPUK3NU41PiCwTR?= NYe4ZoUzW0GQR1XS
ST486 M1LxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jWUGlEPTB;Mkm2MlE1KG6P M2HOW3NCVkeHUh?=
NOMO-1 MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDS[JZ[UUN3ME2zNFAvOjFibl2= MnrkV2FPT0WU
MN-60 NIftPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vkc2lEPTB;M{C1MlMzKG6P M1G5XHNCVkeHUh?=
HCC1187 NWLWbZNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jBd2lEPTB;M{C3MlI2KG6P MnXZV2FPT0WU
SW982 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe4NXg5UUN3ME2zNVQvPzVibl2= NFr5OItUSU6JRWK=
LB647-SCLC NWX3fnVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rRfmlEPTB;M{K4MlcyKG6P M1;sSHNCVkeHUh?=
HC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnFXZhNUUN3ME2zN|UvPSCwTR?= MmDOV2FPT0WU
EHEB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M125cGlEPTB;M{O3MlUzKG6P M3G4THNCVkeHUh?=
TUR NHnkUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXaTWM2OD1|NkOuPVUhdk1? M1\iV3NCVkeHUh?=
LU-139 NVXUXW53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjROXRDUUN3ME2zO|gvODJibl2= M3SxTHNCVkeHUh?=
NB1 M4jjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTN6ND60OUBvVQ>? MUjTRW5ITVJ?
BB30-HNC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O1WGlEPTB;M{i4MlMzKG6P NY\UZlY1W0GQR1XS
HAL-01 M322dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLPTWM2OD1|OEmuNlYhdk1? NYK4enlLW0GQR1XS
K5 NVnQcYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRzMT6zO{BvVQ>? MYHTRW5ITVJ?
MZ2-MEL M{f1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTRzMz62OEBvVQ>? NHW3W3dUSU6JRWK=
RXF393 M4L2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S1bWlEPTB;NEG2MlQ2KG6P NH3tTlRUSU6JRWK=
NCI-H1648 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRzNz61N{BvVQ>? NUn6VmxjW0GQR1XS
TE-12 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTR|ND6yOkBvVQ>? M2\RdXNCVkeHUh?=
EoL-1- M37ETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\xWI8zUUN3ME20N|cvQThibl2= NFK5S2JUSU6JRWK=
JAR M3G5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH1TWM2OD12M{iuOlIhdk1? NV\1d443W0GQR1XS
DSH1 NIDBVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR3OD65NUBvVQ>? MmTIV2FPT0WU
NCI-H187 NXe5V|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3YTWM2OD12NkKuPFEhdk1? NWHR[FlwW0GQR1XS
HCE-4 Ml\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7uTWM2OD12N{euOlYhdk1? MY\TRW5ITVJ?
8-MG-BA MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTV6MT61NkBvVQ>? MVXTRW5ITVJ?
KLE M4DQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7xTWM2OD13OEWuNkBvVQ>? NV\pR496W0GQR1XS
KNS-42 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHKXmFKSzVyPUW4Ok45OSCwTR?= NGrpU4VUSU6JRWK=
MSTO-211H MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL5RolzUUN3ME22NFkvPzRibl2= M1;a[XNCVkeHUh?=
GDM-1 M{DxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PGeGlEPTB;NkG0MlA6KG6P M13veXNCVkeHUh?=
TE-1 NU\nRZZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3rR5FYUUN3ME22OFYvOTJibl2= MVLTRW5ITVJ?
BT-474 NVzIbIpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nPe2lEPTB;NkS3MlA3KG6P NE\0XWRUSU6JRWK=
KARPAS-45 NYPBUnZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK5WlBKSzVyPU[0O{43KG6P M2jJdXNCVkeHUh?=
MOLT-16 NGiyXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX24doVJUUN3ME22OFcvQTNibl2= MX3TRW5ITVJ?
KURAMOCHI NYTPbpVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTZ3Nz61NUBvVQ>? MoT2V2FPT0WU
K-562 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ewS2lEPTB;Nk[5MlUyKG6P MlzXV2FPT0WU
EKVX MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvuTWM2OD14N{KuO|Ehdk1? NYXkcVNsW0GQR1XS
GAK NGLtdnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLsTWM2OD14N{WuN{BvVQ>? M4LyTXNCVkeHUh?=
NCI-SNU-5 M3rCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rjemlEPTB;NkmwMlAyKG6P NH\DfJhUSU6JRWK=
NCI-H2126 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULk[FNjUUN3ME23NlYvQDdibl2= NWrTbHRsW0GQR1XS
CTV-1 M2jGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzzTWM2OD15NESuPUBvVQ>? Mli5V2FPT0WU
SW962 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXBdlNKSzVyPUe0PE41PCCwTR?= M121dHNCVkeHUh?=
MONO-MAC-6 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGyTWM2OD15NU[uPVMhdk1? M3;DXnNCVkeHUh?=
NCI-H748 NFLQb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLvTWM2OD15NUiuPVkhdk1? M1;1N3NCVkeHUh?=
NCI-H524 NG\RbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXQV5NwUUN3ME23PFAvPzNibl2= MlHQV2FPT0WU
LS-123 M{j2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PO[mlEPTB;N{m1MlY6KG6P NE\YVGRUSU6JRWK=
NB7 NEXB[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRThzND6xOEBvVQ>? NUfoSplbW0GQR1XS
LS-1034 NEfRdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKzTWM2OD16MkiuPVghdk1? Mom0V2FPT0WU
TE-5 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvoSXdKSzVyPUi4N{42PiCwTR?= NH;tN|VUSU6JRWK=
A704 M{nmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPQTWM2OD16OUmuNVUhdk1? M3Lx[3NCVkeHUh?=
TK10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf4T2RKSzVyPUmxOk4xOyCwTR?= MkHjV2FPT0WU
NCI-H345 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTl2Mz6yNkBvVQ>? M{nQR3NCVkeHUh?=
CGTH-W-1 M1P4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrifHpuUUN3ME25OFgvOTNibl2= M1zDfnNCVkeHUh?=
NCI-H510A MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\lSWlEPTB;OUi1MlEzKG6P MmOyV2FPT0WU
NCI-H1963 NWe3TlA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwMEOyPVIh|ryP NWPvSJV{W0GQR1XS
SCC-3 M4LtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj6TWM2OD1zLkCzOFE1KM7:TR?= NYrzbmFkW0GQR1XS
EW-11 M3O1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwMEi3OFMh|ryP NEPmOJJUSU6JRWK=
CPC-N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzLZ3NKSzVyPUGuNFg5KM7:TR?= NXPrSZFWW0GQR1XS
NCI-H1417 NUOzXnM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHh[JZKSzVyPUGuNVIzPiEQvF2= MWDTRW5ITVJ?
DG-75 M3XPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUizZ3FkUUN3ME2xMlE3Ojh3IN88US=> M2XUdnNCVkeHUh?=
HD-MY-Z M2fCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMU[0NVYh|ryP MkXGV2FPT0WU
ATN-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrYTWM2OD1zLkK2NlA6KM7:TR?= NF7zPFJUSU6JRWK=
KM-H2 M1TJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\3bHRGUUN3ME2xMlI3PDB6IN88US=> NFLsNnZUSU6JRWK=
NCI-H2081 NUnHdnJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLGRmkzUUN3ME2xMlI3PjN5IN88US=> MUTTRW5ITVJ?
HL-60 NX;GeI5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjKRoZKSzVyPUGuNlY6PTlizszN MWnTRW5ITVJ?
DB NV3CT5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPCTWM2OD1zLkK3NlQzKM7:TR?= MXPTRW5ITVJ?
NCI-H1522 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1yxOmlEPTB;MT6yPFg5PyEQvF2= NXS0[|hFW0GQR1XS
AM-38 NF\4PWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTFwM{C3NkDPxE1? M2O0PXNCVkeHUh?=
NCI-H446 NXi4TGNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:yPJhKSzVyPUGuN|IyOjFizszN NV7ZZVNiW0GQR1XS
SU-DHL-1 NX3le5JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwM{K4NFEh|ryP MnuxV2FPT0WU
NH-12 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLYRYJKSzVyPUGuN|Y{PzRizszN MYTTRW5ITVJ?
DMS-79 NFrPRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmz[FVyUUN3ME2xMlM3QDZ4IN88US=> Ml3QV2FPT0WU
NCI-H716 NI\tbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LjWWlEPTB;MT6zPFk5PiEQvF2= NEnjVo9USU6JRWK=
ML-2 M3y1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF2zNINKSzVyPUGuOFE2OjlizszN M3HxcHNCVkeHUh?=
NB10 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PqfmlEPTB;MT60OlY{OiEQvF2= NX;JeIppW0GQR1XS
ONS-76 M4jLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXaR3FKSzVyPUGuOVM2PjlizszN MlzmV2FPT0WU
LOUCY NXnXR4Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfLTpJtUUN3ME2xMlU1PjV5IN88US=> MVTTRW5ITVJ?
SCLC-21H NYS2NYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe0cJpZUUN3ME2xMlU5PTh{IN88US=> NFPzNZBUSU6JRWK=
TGW NXjnZ4FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4b3Q1UUN3ME2xMlY{QTd3IN88US=> M2r5WXNCVkeHUh?=
LXF-289 M2fuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPCTWM2OD1zLkezNlY5KM7:TR?= MlPGV2FPT0WU
BB49-HNC MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluxTWM2OD1zLkezOVg3KM7:TR?= M2nxPXNCVkeHUh?=
NCI-H747 NUT1S4hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrBNpBKSzVyPUGuO|U{PDZizszN Mlq2V2FPT0WU
LU-165 NHLjUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVX5dI86UUN3ME2xMlg1QTh4IN88US=> MkG0V2FPT0WU
OMC-1 NVPKZodtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GxWWlEPTB;MT65OVA3PiEQvF2= NH\uToFUSU6JRWK=
RCC10RGB NInGUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\hOIl6UUN3ME2xMlk2QDF5IN88US=> M1zueHNCVkeHUh?=
SW684 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPITWM2OD1zLkm2NFk6KM7:TR?= MVrTRW5ITVJ?
TE-8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[yTWM2OD1{LkC1OVU6KM7:TR?= MXXTRW5ITVJ?
SK-N-DZ NX;rSVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTETWM2OD1{LkGzNlc1KM7:TR?= MmPFV2FPT0WU
EVSA-T NXewV2FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqyZppKSzVyPUKuNVc{OTVizszN NFTLPZVUSU6JRWK=
KASUMI-1 NX\YPGRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTXTWM2OD1{LkG4PFE2KM7:TR?= M4nMbHNCVkeHUh?=
NKM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CxN2lEPTB;Mj6yOVQ4OiEQvF2= NVjL[mlJW0GQR1XS
CAL-148 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnKZWY4UUN3ME2yMlM{PjF2IN88US=> NIXxT|NUSU6JRWK=
NCI-H64 NH;L[IJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzhO4tqUUN3ME2yMlM1OjN{IN88US=> MmHYV2FPT0WU
KNS-81-FD M2LHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJwM{[2NkDPxE1? MoTKV2FPT0WU
KM12 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LCN2lEPTB;Mj60NFg{QSEQvF2= NYP0TZhsW0GQR1XS
SW954 NEm1bnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT4Z41uUUN3ME2yMlQ4Pzd7IN88US=> M1fhRnNCVkeHUh?=
NCI-H1395 M4TUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETqUpRKSzVyPUKuOVI3PDVizszN MlPmV2FPT0WU
DJM-1 M3PNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjzNZc2UUN3ME2yMlYxPjNizszN NY\ZZ4dCW0GQR1XS
COLO-668 NEfGTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf1b5hTUUN3ME2yMlgzPjl3IN88US=> M1\PRXNCVkeHUh?=
NCI-H1436 NHLRSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4POVWlEPTB;Mj64OVYyPSEQvF2= MULTRW5ITVJ?
LB2241-RCC NV23dZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwOE[4N|kh|ryP MoHDV2FPT0WU
GT3TKB M3nvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX6WXdKSzVyPUKuPFkxPTVizszN MofzV2FPT0WU
COLO-824 NI\ISGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJwOEm3Olgh|ryP NH7lNHhUSU6JRWK=
ES1 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwOEm4O|kh|ryP MnfJV2FPT0WU
LB771-HNC NF\3XW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLhOHlHUUN3ME2yMlkxQTR4IN88US=> MY\TRW5ITVJ?
GI-ME-N NXj2VJVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGwbItKSzVyPUOuNFA6ODRizszN MUnTRW5ITVJ?
NALM-6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknETWM2OD1|LkCwPVM{KM7:TR?= NIP6XHVUSU6JRWK=
LU-134-A NX\uXHF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\5OFhKSzVyPUOuNFU1OjVizszN MUjTRW5ITVJ?
DMS-153 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjlcGtGUUN3ME2zMlA2QDJ2IN88US=> NXfrenNoW0GQR1XS
MZ1-PC NV:yeYxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTNwMEmwO|gh|ryP NIPtPI1USU6JRWK=
NCI-H1155 NFHRN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwMUG2NUDPxE1? M2P3ZnNCVkeHUh?=
CAS-1 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHJ[49KSzVyPUOuNVM4ODdizszN NYXCSnlHW0GQR1XS
D-502MG MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j2R2lEPTB;Mz6xOFM6KM7:TR?= MlPlV2FPT0WU
NCI-H2141 M{PnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNwMUe0OVIh|ryP NVnlbolCW0GQR1XS
NB6 MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHUd3BKSzVyPUOuNVgzPTlizszN M2LpbnNCVkeHUh?=
NCCIT Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3pdI9KSzVyPUOuNlE5ODlizszN NYPsbWVJW0GQR1XS
NB69 NIrO[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f2U2lEPTB;Mz6zNVg6OSEQvF2= M3v2U3NCVkeHUh?=
JVM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwM{[0N|Mh|ryP NWTuWlFsW0GQR1XS
K052 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfLU3V{UUN3ME2zMlM4QTZ6IN88US=> NXX0[nZLW0GQR1XS
HCC2157 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jMcWlEPTB;Mz61N|IzQCEQvF2= MX\TRW5ITVJ?
KMOE-2 MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj1coFKSzVyPUOuOVQzPDJizszN MXXTRW5ITVJ?
SF268 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwN{G1OVQh|ryP MnTrV2FPT0WU
CHP-126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLOOIVKSzVyPUOuO|Y1PThizszN MlzLV2FPT0WU
CP66-MEL M1PXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LYdmlEPTB;Mz63PVA6PCEQvF2= MkS0V2FPT0WU
NCI-H69 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwMEG5N|Yh|ryP MVzTRW5ITVJ?
A253 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7XbYtKSzVyPUSuNFIyODFizszN MWPTRW5ITVJ?
NB14 M1rIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLDVoFUUUN3ME20MlExPDd7IN88US=> M3K0[XNCVkeHUh?=
NCI-H1694 NH3PTWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXoTWM2OD12LkGzNVEzKM7:TR?= MnizV2FPT0WU
NCI-H2196 M1\xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRwMUexOlkh|ryP MY\TRW5ITVJ?
TE-9 M374Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\6SXBKSzVyPUSuNVc2QDJizszN MX;TRW5ITVJ?
D-283MED NVrOR5AzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPQSpFKSzVyPUSuNVg5PCEQvF2= NHT4XppUSU6JRWK=
OCI-AML2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnSd5lOUUN3ME20MlE6PDh7IN88US=> NEn3Z2RUSU6JRWK=
D-263MG NXzafmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXNUmtwUUN3ME20MlIzQTZzIN88US=> M2DXWnNCVkeHUh?=
MPP-89 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETVc|FKSzVyPUSuNlc{ODRizszN MlqzV2FPT0WU
LAMA-84 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG4TWM2OD12LkOwOFIyKM7:TR?= NV75S2JwW0GQR1XS
LB373-MEL-D MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3[4VmlEPTB;ND6zOlc5QSEQvF2= MXPTRW5ITVJ?
UACC-257 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHrco9OUUN3ME20MlM6PTN2IN88US=> MoL3V2FPT0WU
MC-CAR NVTDR4tTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLh[ZdYUUN3ME20MlQ{QTlizszN M4DNUHNCVkeHUh?=
COLO-320-HSR M1XaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n2SWlEPTB;ND60OFQzPyEQvF2= MYnTRW5ITVJ?
P30-OHK Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRwNk[1PFEh|ryP NFnzUINUSU6JRWK=
UACC-812 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXONpU1UUN3ME20MlY6OTZzIN88US=> NU\GXm57W0GQR1XS
CTB-1 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXqTI5KSzVyPUSuO|E2PTVizszN MYnTRW5ITVJ?
ALL-PO MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwOESwO|ch|ryP MXXTRW5ITVJ?
SK-MEL-2 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjqWZpKSzVyPUSuPFY6PTVizszN M1\NOXNCVkeHUh?=
TC-YIK NFXoVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qzNWlEPTB;ND65O|k1OiEQvF2= NIfVNlJUSU6JRWK=
NCI-H1882 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGyTWM2OD13LkCyNFAyKM7:TR?= M2rBdXNCVkeHUh?=
MHH-CALL-2 NUC0XIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTVwMEWwOFIh|ryP NX:w[mRUW0GQR1XS
U-87-MG NWTwWJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\BOZY2UUN3ME21MlA6PDZ4IN88US=> NWLz[JUzW0GQR1XS
NCI-H1092 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTVwMk[1OVUh|ryP NHnzfo1USU6JRWK=
TE-441-T NWf2enN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK2UWtKSzVyPUWuNlc5OiEQvF2= M{PFSXNCVkeHUh?=
SK-MEL-1 NUDTZ|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrm[4xPUUN3ME21MlI6ODR2IN88US=> NY[0eWlzW0GQR1XS
EW-22 Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PHOGlEPTB;NT6yPVQ3PiEQvF2= MkWxV2FPT0WU
MZ7-mel NV[wTIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrxTWM2OD13LkSwOlkyKM7:TR?= MnjnV2FPT0WU
LP-1 NWX5c|VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknqTWM2OD13LkSxNlkyKM7:TR?= MXzTRW5ITVJ?
NCI-SNU-16 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnwXopKSzVyPUWuOlQxPzRizszN NVHqZVlnW0GQR1XS
LU-65 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPRXmxZUUN3ME21Mlc3Ozd|IN88US=> NYnHcpk1W0GQR1XS
CW-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT4T3JmUUN3ME21Mlg2QTV7IN88US=> M3XCOnNCVkeHUh?=
WSU-NHL NHvFbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:3TWM2OD13Lkm1NVc1KM7:TR?= NEL3OlJUSU6JRWK=
IST-MES1 NVnmVpZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTVwOUW0OFMh|ryP NXHDeVdNW0GQR1XS
U-266 M1rzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PUbWlEPTB;NT65PFIxOiEQvF2= NF\vVlFUSU6JRWK=
TALL-1 M33CR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3PZXdsUUN3ME22MlE1Pjh6IN88US=> MnfpV2FPT0WU
Calu-6 NIq2TnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK2TWM2OD14LkG1N|E3KM7:TR?= NYXsS2JTW0GQR1XS
MMAC-SF MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W2XmlEPTB;Nj6xPFU2PiEQvF2= MnPDV2FPT0WU
NCI-H82 NWXsUmVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZwMkC0PFkh|ryP MVXTRW5ITVJ?
RS4-11 NEfuTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XCNGlEPTB;Nj6yOVg6PyEQvF2= NVm0b3pjW0GQR1XS
SNU-C2B M1TtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDNU4dNUUN3ME22MlQxQTZ7IN88US=> MYjTRW5ITVJ?
BOKU NYjpTIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETuNIRKSzVyPU[uOFc2QTdizszN M4DaS3NCVkeHUh?=
C8166 NVS1[3NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHwTWM2OD14LkW1PVEzKM7:TR?= Ml\SV2FPT0WU
D-247MG NGHQO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX6TWM2OD15LkC0N|Q4KM7:TR?= MmL1V2FPT0WU
EW-18 NYX2XJJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnXTWM2OD15LkC3NlkzKM7:TR?= MWnTRW5ITVJ?
KG-1 NIDk[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW3[mV1UUN3ME23MlYzPzN6IN88US=> NWTabmh{W0GQR1XS
REH NFPvNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnMbIZkUUN3ME23MlY5OTB7IN88US=> MWnTRW5ITVJ?
U-698-M NWXIbpdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r2UGlEPTB;Nz64OFMyPSEQvF2= MUXTRW5ITVJ?
KP-N-RT-BM-1 NVe0WVBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIntbI1KSzVyPUeuPVMxOjlizszN M2rZT3NCVkeHUh?=
MS-1 NHruVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rSfGlEPTB;Nz65OlA1OSEQvF2= NV;FOW12W0GQR1XS
SNU-C1 NV\LVlZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;NTWM2OD15Lkm4NVkzKM7:TR?= NE\tdYRUSU6JRWK=
SK-MM-2 MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13M[2lEPTB;OD6yOlA3PSEQvF2= M362dHNCVkeHUh?=
LAN-6 NHTKd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjvTWM2OD16LkOwNFAyKM7:TR?= NEfHdYNUSU6JRWK=
NEC8 NY[zZ2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjMTXRKSzVyPUiuN|A3QTFizszN MXHTRW5ITVJ?
NCI-H1770 NUGyNlV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjRenhDUUN3ME24MlM5ODB{IN88US=> M3jU[XNCVkeHUh?=
D-336MG NET4bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRThwNECxNVYh|ryP MorVV2FPT0WU
COLO-829 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqzU|ZKSzVyPUiuOFg5PzlizszN MVzTRW5ITVJ?
LS-513 NEDJd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjTc5NqUUN3ME24MlU6PTl7IN88US=> MVPTRW5ITVJ?
YT MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH5TWM2OD16Lk[yOFI4KM7:TR?= MkDYV2FPT0WU
EW-24 M2HoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfTd5p1UUN3ME24Mlc3PTRizszN NGHpd3NUSU6JRWK=
IST-SL1 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3TRWVKSzVyPUiuPFY2PDNizszN NXS2SGdpW0GQR1XS
CA46 M4jDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW4TWM2OD16Lkm1NFk5KM7:TR?= MYDTRW5ITVJ?
NCI-H1838 NVHEfZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRThwOUi2NFIh|ryP MVHTRW5ITVJ?
NCI-H719 NYD2fHY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXQTWM2OD17LkK1Nlc6KM7:TR?= MYrTRW5ITVJ?
HCE-T NV7SVpJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTlwM{C4OVEh|ryP NFP2XZZUSU6JRWK=
A498 Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTlwM{[xNlQh|ryP NVj3[44yW0GQR1XS
LB831-BLC NWTrfVRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTlwN{[1NlEh|ryP NXjnd3RGW0GQR1XS
SKM-1 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTlwOEW5OlMh|ryP MkHwV2FPT0WU
THP-1 NFjJT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX6TWM2OD17Lkm2PVE5KM7:TR?= NGXl[I1USU6JRWK=
SHP-77 M4fKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\te|lKSzVyPUGwMlQxPyEQvF2= NGKzZoxUSU6JRWK=
EW-3 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfNTWM2OD1zMD62Nlg6KM7:TR?= NWTUVlQ{W0GQR1XS
KY821 M2G0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LVWWlEPTB;MUCuO|Y{KM7:TR?= MWHTRW5ITVJ?
NCI-SNU-1 NVPYcG1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFzLkCyNVch|ryP MmPDV2FPT0WU
HCC2218 NVq5N5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfXTWM2OD1zMT6zPVg3KM7:TR?= MWPTRW5ITVJ?
IM-9 NHnpVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3FeGN3UUN3ME2xNU42OTB4IN88US=> Mkm0V2FPT0WU
NCI-H889 MmfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfvdphKSzVyPUGxMlU{OTNizszN NUH5ZWxRW0GQR1XS
HDLM-2 M17yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml72TWM2OD1zMj60NVU6KM7:TR?= MUnTRW5ITVJ?
LB2518-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES2XFlKSzVyPUGyMlY5OTVizszN M{P6eHNCVkeHUh?=
NCI-H23 NUn0PJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16yVWlEPTB;MUOuNlQzPSEQvF2= MojPV2FPT0WU
NB17 M2DMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\BSlJKSzVyPUGzMlQ2PzlizszN MXPTRW5ITVJ?
NCI-H322M MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXDOnFEUUN3ME2xOE41ODZ6IN88US=> MXrTRW5ITVJ?
SUP-T1 NX3Jclc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\GSoNKSzVyPUG0MlQyOyEQvF2= NVny[ZZsW0GQR1XS
ES3 NI\pZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zI[WlEPTB;MUWuNFcxOyEQvF2= MUTTRW5ITVJ?
ES5 NYnwfWdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nnSGlEPTB;MUWuNFc5PyEQvF2= M2TNenNCVkeHUh?=
NCI-H1650 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF3LkS5O|kh|ryP MY\TRW5ITVJ?
NCI-H226 M2DPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvlPGw1UUN3ME2xOU45PzZ6IN88US=> NXvOdG1nW0GQR1XS
COR-L88 M3j2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPyfVBrUUN3ME2xOk4{OTRizszN NXfrfpd1W0GQR1XS
SCC-15 M3z1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nJcGlEPTB;MU[uN|g3QSEQvF2= NX3yTY9{W0GQR1XS
GOTO NUG4clYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fwcmlEPTB;MU[uOFc6OyEQvF2= Ml3qV2FPT0WU
SIMA NGLOfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3JOYo6UUN3ME2xOk41QDB{IN88US=> NUTMRnAzW0GQR1XS
NCI-H1299 NFrlfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTF5LkG1PVEh|ryP Mnq0V2FPT0WU
NCI-H1581 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7NTWM2OD1zNz60NlE6KM7:TR?= MlP0V2FPT0WU
MHH-NB-11 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnHTWM2OD1zNz65Olg{KM7:TR?= M4TWfXNCVkeHUh?=
MFM-223 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPQTZZKSzVyPUG4MlA2OzhizszN MX3TRW5ITVJ?
ES7 NV:0UFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPXTWM2OD1zOD61OFMyKM7:TR?= NWHI[JdOW0GQR1XS
JVM-3 NVL2[2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL4TGhKSzVyPUG4MlcyPyEQvF2= Ml\SV2FPT0WU
RL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJyLkO4PEDPxE1? NGfIfmdUSU6JRWK=
EC-GI-10 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrWcoNKSzVyPUKxMlIxPDFizszN NXKxdlVJW0GQR1XS
LNCaP-Clone-FGC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJzLk[3Olgh|ryP NFrHVpBUSU6JRWK=
IMR-5 M1XSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3OfWwyUUN3ME2yNU45PDl2IN88US=> M4jOXHNCVkeHUh?=
KP-N-YS NVrY[ZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULKVpFZUUN3ME2yNU45PzVizszN MUjTRW5ITVJ?
Mo-T Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfSUoJGUUN3ME2yNk4zOTh3IN88US=> NYX6XoZCW0GQR1XS
NCI-H128 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3KTWM2OD1{Mz61PFU{KM7:TR?= NXLteZdtW0GQR1XS
RH-1 M3u1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HiWmlEPTB;MkOuO|g3PiEQvF2= NHjiO4NUSU6JRWK=
NCI-H2171 M4j6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ2LkK0PFUh|ryP NGTSdoNUSU6JRWK=
RPMI-8866 M{LZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DCN2lEPTB;Mk[uO|QzKM7:TR?= NViybY1ZW0GQR1XS
SK-N-FI MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qwfWlEPTB;MkeuN|gyOSEQvF2= NGPPcHdUSU6JRWK=
LOXIMVI M3jJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJ5LkiwOVEh|ryP M2TXVnNCVkeHUh?=
P31-FUJ MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTNzLkWzO|Qh|ryP NFLJO2dUSU6JRWK=
KMS-12-PE MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTR7LkWzNFIh|ryP NV\KXIRoW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

プロトコル(参考用のみ)

キナーゼアッセイ:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞アッセイ:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物実験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
体内 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
in solvent
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

mTOR信号経路図

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID